EnGene's shares crash on updated pivotal bladder cancer data
EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech's shares {$ENGN} fell 80% Thursday morning after reporting ...
May 7, 2026 11:44 AM EDT R&D EnGene's shares crash on updated pivotal bladder cancer data Lei Lei Wu News Reporter EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that